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ABSTRACT 
 
As one of the world’s most devastating viruses, HIV-1 has killed more than 
39 million people, and around two million cases of newly infected individuals are 
recorded every year. However, no effective vaccine has been developed to stop 
this pandemic since its onset in the 1980s. Since vaccine development is moving 
slowly, delivery platforms as an essential element to enhance both the efficiency 
and efficacy of vaccines have drawn increased attention. Gold nanoparticles 
(GNPs) as a novel delivery platform has been studied in drug and vaccine 
delivery. My research goal is to apply this delivery platform in the AIDS vaccine 
development field for HIV-1 envelope protein-based subunit antigens.  
We studied different conjugation methods to load antigens on GNPs. First, 
we tried to directly link an antigen onto GNPs through an introduced cysteine 
mutation in the antigen, since the thiol group of cysteine can form a covalent 
bond with GNP. In this direct-linking study, we made several antigen variants 
with cysteine introduced in different positions of the original antigen. All cysteine 
variants can be successfully loaded on GNPs, with neutralizing epitopes exposed 
after bond on GNPs. We found that the terminal cysteine variants (with the 
cysteine mutation on either end of the antigen) can elicit high antibody response 
in rabbits; however, the antibody responses from the internal cysteine variants 
(with the cysteine mutation inside of the antigen) are exceptionally low. We 
suspected that the antigens loaded on GNPs trough the internal linkage might be 
too close to the GNP surface, therefore, it might be difficult to cleave these 
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protein antigens from the GNPs in vivo by the protease in the endosome, which 
could result a low immune response.   
To further enhance the antibody response, we hypothesized that a spacer 
between the GNP and antigen might be needed instead of direct linkage. We 
speculated that a linker between the antigen and GNP might promote antigen 
processing in the immune system after the antigen-loaded GNPs have been 
taken by the antigen presenting cells (APCs), which could assist in eliciting high 
immune responses. Therefore, we examined two linkers for our antigens to 
attach onto the GNPs. Again, our antigen can be successfully loaded on the 
GNPs through these linkers, with the critical neutralizing epitope exposed even 
after loading on the GNPs. After the pilot animal experiment, we chose the N-
[Nα,Nα-Bis(carboxymethyl)-L-lysine]-12-mercaptododecanamide (SH-NTA) linker 
to continue our immunization studies in both mice and rabbits. As expected, 
compared to the protein-only immunized group, the protein-on-GNP group 
exhibited a much higher antibody titer reaching 107 after only three 
immunizations in two animal models. Neutralizing activity was also detected in 
rabbits. Our result suggests that the GNP-NTA system as a delivery platform 
could preserve the critical epitopes of the loaded antigen as well as elevate their 
antibody responses. Since our GNP-NTA platform was designed to deliver any 
protein-based antigen, the positive results from our study indicate that our GNP-
NTA delivery system has great potential to be applied in protein-based vaccine 
development. 
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CHAPTER 1 GENERAL INTRODUCTION 
 
1.1 Dissertation Organization 
Chapter 1 is the General Introduction, which covers the basic information 
for both Human Immunodeficiency Virus type 1(HIV-1) and vaccine delivery 
platforms. An overview is provided that includes the HIV-1 pandemic’s history, 
HIV-1 subtypes, and HIV-1 genome proteins, with an emphasis on the envelope 
protein. This is followed by information on the current strategies for developing 
HIV-1 vaccines and clinical trials. Gold nanoparticles (GNPs) are used in my 
thesis for vaccine delivery; therefore, an overview is given to several popular 
delivery platforms, then a detailed review is given to GNP synthesis, different 
coating agents and linkers on the GNP surface, and a summary of its application 
in vaccine delivery.  
Chapter 2 is a manuscript in preparation, “Assessing the immune 
response of HIV-1 gp41-based antigens delivered on gold nanoparticles,” which 
describes the immune responses elicited in rabbits using GNPs to a deliver HIV-
1 gp41 based antigen, using different orientations of the protein on GNPs as 
determined by the inclusion of a cysteine amino acid. Different responses were 
identified using different cysteine variants. The contributions of each author to the 
paper are as follows: Habtom Habte and I carried out immunization studies, 
Habtom Habte generated the terminal mutants, I generated the internal mutants 
and conducted the antigenicity and immunogenicity tests for all mutants, Keiji 
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Takamoto helped with the GNPs binding protocol, and Michael Cho and I wrote 
and revised the manuscript.  
Chapter 3 is a manuscript in preparation, “Development of a novel antigen 
delivery platform based on gold nanoparticles to induce potent antibody 
responses,” which describes using the N-[Nα,Nα-Bis(carboxymethyl)-L-lysine]-
12-mercaptododecanamide (SH-NTA) linker to deliver a gp120 based antigen, 
ODx3, on GNPs. Animal experiments were carried out in both mice and rabbits, 
with strong antibody responses elicited in both animal models. Neutralizing 
activity was detected in rabbit sera after the third immunization. The contributions 
of each author to the paper are as follows: I carried out all the immunization 
studies, Habtom Habte helped to establish the protocol for linker binding, Yali Qin 
provided the antigen, Kari Rohl helped to run the agarose gel and antigenicity 
tests of the antigen loaded on GNPs, Feng Jiao helped with the neutralizing 
assay, Keiji Takamoto designed the SH-NTA linker, and Michael Cho, Kari Rohl 
and I wrote and revised the manuscript.  
Chapter 4 is the Conclusion chapter that states general conclusions as 
well as implications for future work.  
 
1.2 HIV and Vaccine Research  
1.2.1 History of The HIV Pandemic 
Acquired Immunodeficiency Syndrome (AIDS) was first recognized in Los 
Angeles in 1981 [1,2]. Two years later, the responsible retrovirus was isolated at 
the Pasteur Institute in France [3]. This virus was later named Human 
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Immunodeficiency Virus (HIV) by the International Committee on Taxonomy of 
Viruses in 1986 [4]. HIV is a devastating virus, which has claimed more than 39 
million lives since the start of the epidemic. In the most resent global report from 
the Joint United Nations Program on HIV/AIDS (UNAIDS), there were 35 million 
people living with HIV with 2.1 million people becoming newly infected in 2013 
(http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet).  
 
1.2.2 HIV Subtypes and Global Pandemic 
HIV is subdivided into HIV-1 and HIV-2. Compared to HIV-1, HIV-2 is 
much less virulent [5] and mostly confined in western Africa [6]. Therefore, HIV-1 
is the major research target in the efforts to cure AIDS. HIV-1 can be further 
divided into groups: M (major), O (outlier), N (non-M, non-O) [7] and P (putative) 
[8,9]. Group M causes over 95% of infections worldwide and accounts for the 
vast majority of the global pandemic [10]. This group has 9 clades (A, B, C, D, F, 
G, H, J, and K), 51 circulating recombinant forms (CRFs, hybrid viruses that have 
genetic material from two or more clades and infect more than one person), and 
many unique recombinant forms (URFs, hybrid viruses only exist in one 
individual patient) [11]. These clades show geographically evident distribution 
patterns. For example, Clade B is prevalent in North America and Europe, while 
clade C is prevalent in South Africa and South Asia (Figure 1.1). 
The HIV-1 group M subtypes were originally divided according to their 
phylogenetic relationships [12]. The distribution locations of each subtype is 
shown according to the 2003-2007 global distribution [13] (Figure 1.1). Clade C 
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viruses are the most prevalent subtype, which accounts for 48% of total 
infections. Clade A and clade B are the other two dominant clades, which each 
account for more than 10% of infections (12% and 11%, respectively). Other 
clades are less prevalent, and they are generally found only in Africa. CRFs are 
also a growing threat, including AE, which makes up 5% of infections and is 
found mainly in East Asia.  
 
 
Figure 1.1: HIV-1 subtypes and distribution 
Schematic representation of the phylogenetic relationship between the subtypes in M group and 
their major distribution regions worldwide.  
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1.2.3 Course of Infection 
Unlike other viruses, HIV-1 cannot be eliminated by our own immune 
system following infection, because this lethal virus directly destroys the human 
immune system by infecting helper T cells (CD4 T cells) [14], macrophages [15], 
and dendritic cells [16], which all have the CD4 receptor required for HIV-1 
infection. HIV-1 virus infection typically results in the depletion of helper T cells 
[17] that play a crucial role in regulating immune responses by releasing T cell 
cytokines. These cytokines are responsible for mediating both humoral immunity 
and cellular immunity by activating leukocytes like B cells, cytotoxic T cells (CD8 
T cell) and macrophages [18]. Therefore, after the CD4+ lymphocyte cell number 
drops under 200 per mm3 in the blood following prolonged HIV-1 infection [19], 
the patients become more susceptible to opportunistic infections because of the 
collapse of the immune system [20]. This leads to the final stage of HIV-1 
infection known as AIDS, which finally results in the patient’s death (Figure 1.2). 
 
 
Figure 1.2: Typical course of HIV-1 infection 
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The blue line indicates the CD4 T cell count (cells per mm3), the red line indicates the HIV-1 RNA 
copies per ml of plasma, and the green line indicates the detectable viremia. Adapted from [21]. 
 
1.2.4 HIV-1 Genome 
The HIV-1 genome is RNA-based with a size around 10kb, which encodes 
15 different proteins [22] (Table 1.1).  
Gag and Env are basically structure components of the viral core and the 
outer membrane envelope. Pol provides necessary enzymatic function. Other 
regulatory and accessory proteins also assist the virus function in many different 
ways [23] as shown in Table 1.1.  
 
Table 1.1: Proteins encoded by HIV-1 genome 
Name Subunits/ Size Function 
Gag (Group 
specific 
antigen/p55) 
MA (matrix)/p17 Stabilizes viral particles; 
escorts viral DNA to the nucleus [24] 
CA (capsid)/p24 Conical core of viral particles; 
essential for viral replication [25] 
NC (nucleocapsid)/p7 Packages viral RNA [26]; 
facilitates reverse transcription [27] 
P6 Helps Vpr incorporate into assembling virions 
[28] 
Env 
(envelope/ 
gp160) 
GP120 and GP41 Explained in Section 1.2.5 below 
Pol 
(polymerase) 
PR (protease) 
/p10 [29] 
Cleaves of the Gag and Gag-Pol polyprotein 
precursors [30] 
RT (reverse transcriptase) 
/p51 and p66 (with the 
RNase H domain/p15) [31] 
Polymerase activity of reverse transcription; 
Rnase H removes the viral RNA templates 
[32] 
IN (integrase)/ p31 Mediates the insertion of the HIV-1 proviral 
DNA to infected cell genome [33] 
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Table 1.1 continued 
Regulatory 
proteins 
Tat (transcriptional 
transactivatitor)/p14 and 
p16 
Essential for HIV-1 replication [34] 
Rev (regulator of virion 
gene expression)/p19 
Regulates HIV-1 gene expression [35] 
Accessory 
proteins 
Nef (negative effector)/p25-
p27 
Down regulation of CD4 [36] and class I MHC 
[37] 
Vif (viral infectivity factor) 
/p23 
Affects virus infectivity [38] 
Vpr (viral protein r) /p10-p15 Influences the nuclear localization of viral 
genome in non-dividing cells [39]; 
blocks cell division [40] 
Vpu (viral protein u) /p16 Induces CD4 degradation and enhances virus 
release from cell [41] 
 
1.2.5 HIV-1 Envelope 
Of all these different proteins, Env is the main target for antibodies 
because it is the only HIV-1 genome encoded protein located outside the viral 
membrane [42], and thus is accessible to the immune system. The env gene 
encodes for a precursor glycoprotein called gp160, which is later processed by a 
host cell protease into the surface subunit (SU) gp120 and the trans-membrane 
subunit (TM) gp41 [22,43] ( Figure 1.3). 
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Figure 1.3: HIV-1 virus structure and schematic map of the Env protein 
HIV-1 Env is composed of gp120 and gp41. Gp120 is made of five constant regions (C1-C5) and 
five variable regions (V1-V5). SP stands for signal peptide, FP stands for fusion peptide, HR1 and 
HR2 are the heptad repeat region 1 and 2, MPER stands for membrane proximal external region, 
TM stands for trans-membrane domain, and CT is the cytoplasmic tail. 
 
On the HIV-1 surface, gp120 forms a trimer, which is non-covalently linked 
to the trimeric gp41 to form hetero-oligomeric spikes. The binding of gp120 to the 
receptors on cell surface initiates the viral entry. The major receptor is CD4, and 
there are two main co-receptors: C-C chemokine receptor type 5 (CCR5) and C-
X-C chemokine receptor type 4 (CXCR4). HIV-1 can be classified into three 
different tropisms, R5 (use CCR5 for cell entry), X4 (use CXCR4 for cell entry), 
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and R5X4 (use both R5 and X4 for cell entry) [44]. Gp120 can be divided into 
three structural domains: the outer domain (OD), the inner domain, and the 
bridging sheet. It also contains five variable regions (V1-V5) and five constant 
regions (C1-C5) (Figures 1.3 and 1.4).  
 
 
Figure 1.4: Structure of gp120 
The two identical gp120 structures are colored to differentiate the labeled functional regions. 
These two structures are based on the crystal structure in Protein Data Bank (PDB: 4NCO). 
 
Although around 50% of gp120 is covered by a glycan shield [45], there 
are still many exposed portions that can be targeted by broadly neutralizing 
antibodies bnAbs (Table 1.2). 
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Table 1.2: Regions in gp120 targeted by bnAbs  
Region name Representative Binding bnAbs Comments [46-48] 
CD4 binding site 
(CD4bs) 
HJ16, 3BNC117/60, NIH45-46, 
VHH J3, VRC01, b12 [46-49] 
Binding pocket for CD4 receptor; the 
most potent and broad neutralizing 
antibodies target this area. 
CD4-induced site 
(CD4i) 
3BC176 [50], 
17b [51] 
Once the envelope binds to CD4, 
induced epitopes will appear due to 
conformational changes. 
V1/V2 loop PG9/PG16 [52] Highly variable and immunogenic; 
tends to shield the CD4bs. 
V3 loop 447-52D [53], 
257-D [53] 
A semi-conserved region, it can 
interact with the chemokine 
receptors on the target cell surface. 
Carbohydrate 
motif 
 
2G12 [54] Glycan shied is poorly immunogenic; 
only one bnAb has been isolated.  
N332 supersite PGT121 [55], 
PGT135 [56] 
Antibodies target epitopes on both 
the protein and glycan site N332 
gp120-gp41 
interface 
8ANC195 [57], 
35O22 [58] 
Antibodies target epitopes on both 
gp120 and gp41 
 
Another component of the Env is gp41. Gp41 is composed of a fusion 
peptide (FP), fusion peptide proximal region (FPPR), two heptad repeats (HR1 
and HR2), membrane proximal external region (MPER) and the trans-membrane 
region (TM), and the cytoplasmic tail (CT) [59,60] (Figure 1.3). This glycoprotein 
plays an essential role in the fusion step of the virus cell entry [61]. During the 
HIV-1 fusion process, the structure of glycoproteins changes. Gp41 will go 
through three major different stages: pre-fusion, fusion intermediate, and post-
fusion (see Figure 1.5). The fusion intermediate state is the most vulnerable 
state, which can be more easily targeted by bnAbs than the other two states [62]. 
Currently, there are four bnAbs (4E10 [63], 2F5 [64], Z13e1 [65] and 10E8 [66]) 
isolated against gp41, and they all target the MPER. However, this stage is 
highly transient, and gp41 can quickly move to the post-fusion state, in which 
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HR1 and HR2 fold together and form the six-helix bundle [67]. The HIV-1 virus is 
resistant to the bnAbs attack after the post-fusion state, since the virus genome 
will be inside the target cell when the fusion process completes. The fusion step 
is a crucial step of the HIV-1 life cycle, after the fusion, the viral RNA will be 
reverse-transcripted into DNA and integrated into the host cell genome with the 
help of the viral reverse transcriptase and integrase. The integrated viral genome 
(called provirus) can produce more viral proteins to make more viruses and infect 
other healthy CD4+ cells to spread the infection. 
 
 
Figure 1.5: HIV-1 fusion process 
HIV-1 fusion occurs with the assistance of receptors on the host cell surface. Adapted from [68]. 
 
1.2.6 HIV Vaccine  
HIV-1 is lethal because it directly destroys the immune system. 
Significantly, the virus has extensive genetic variations caused by a dramatic 
mutation rate [69], which means that HIV-1 can quickly grow resistant to medical 
treatments, resulting in the current global pandemic. To try and stop the 
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pandemic, HIV-1 has been studied extensively during the past three decades 
[70]. The introduction of highly active antiretroviral therapy (HAART) is a 
significant milestone during history of the fight against HIV. While patients do 
survive longer under the HAART treatment [71,72], there is still no way to 
eradicate the virus through drugs alone. Vaccines, however, as “one of the 
greatest achievements of modern medicine” [73], can completely eradicate the 
prevailing diseases caused by viruses. There are some successful vaccines 
against viruses like smallpox and polio [74], however, vaccine research in the 
HIV-1 field is still proceeding slowly and with only limited success in human trials 
[75]. Nevertheless, as the only hope to prevent virus spread before infection, 
vaccine research against HIV-1 continues.  
The concept of vaccination is best described as a prophylaxis to prepare 
the body for virus infection. After vaccination, a small portion of effector B and T 
cells can develop into memory B and T cells that can “remember” the vaccine as 
the corresponding virus [76]. Thus, when infection occurs later, those memory 
cells can be quickly activated to launch immune responses, such as secreting 
neutralizing antibodies (nAbs), to eliminate the foreign viruses. As mentioned 
earlier, the HIV-1 Env protein is the sole component exposed on the virion 
surface, and is therefore the only target for vaccine elicited nAbs [77]. Thus, the 
Env protein is widely used in HIV-1 vaccine development to elicit bnAbs [47].  
To elicit neutralizing antibodies, many studies have designed antigens, 
which included a variety of bnAb epitopes. Zhang et al. [78] used synthetic HIV-1 
MPER peptides containing the epitopes of 4E10 and 2F5 to immunize guinea 
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pigs, and they observed broad neutralizing activity against several tier 1 viruses 
and three tier 2 viruses after four times of immunizations. Bhattacharyya et al. 
[79] designed two antigens, which were derived from small fragments of HIV-1 
gp120 that covered about 70% of b12 epitope. These two antigens were 
produced in E. coli with very high yield (20mg/L), and although only partially 
folded, could still bind to b12 but not the CD4bs-directed non-neutralizing 
antibody b6. Surprisingly, although sera antibody tier only reached to 105 after 
four immunizations with either antigen, broad and potent neutralizing activity 
against nine tier 2 and tier 3 viruses, and many other tier 1 viruses were elicited 
in rabbits.  
Since HIV-1 has multiple subtypes and a highly variable genome, other 
strategies to elicit cross-clade neutralizing activity are to design antigens using a 
consensus sequence derived from many different clades, or to develop a cocktail 
vaccine that includes many different antigens together. Qin et al. [80] designed 
two gp120 outer domain antigens (OD and ODx3) based on an M-group 
consensus sequence. While still maintaining strong binding to most gp120 
targeting bnAbs, these antigens could also elicit strong antibody responses with 
a titer over 106 after only two immunizations in rabbits. BnAbs against multi-clade 
tier 1 viruses were also elicited. Bricault et al. [81] designed several clade C HIV-
1 gp140 trimers with different antigenic properties. They found that a quadrivalent 
cocktail of the trimers could elicit better neutralizing activity than any single trimer 
in guinea pigs. 
Although the results from animal models are inspiring, we have yet to 
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achieve any significant success in human clinical trials. From over 200 trials, only 
five advanced to phase IIb and III clinical trials. To date, only one trial, the RV144 
demonstrated limited efficacy [82]. This phase III trial used a recombinant HIV-1 
(env-gag-protease) carnarypox vector vaccine to prime four times followed by 
boosting twice with a gp120 protein subunit vaccine [83]. After three years of 
testing 16,402 subjects, this trial demonstrated a modest 31.2% efficacy in 
preventing HIV-1 infection.  
While HIV-1 vaccine development continues to move slowly, attentions 
have also been drawn to novel vaccine delivery platform development. My thesis 
work focuses on developing a GNP-based delivery platform for HIV-1 vaccines. 
Therefore, several common delivery platforms for vaccines, especially the GNP 
delivery platform is overviewed in the following section.  
 
1.3 Vaccine Delivery Platform 
1.3.1 Delivery Platform Overview 
Delivery platform choice is of crucial importance to improve the efficiency 
and efficacy of a candidate vaccine. Currently there are several popular delivery 
platforms including biological platforms such as DNA plasmid and recombinant 
viral vectors; and organic/inorganic materials such as immunostimulating 
complexes (ISCOMs), polymer, lipid and metal-based delivery platforms (see 
Figure 1.6). 
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Figure 1.6: Schematic view of different nanoparticle delivery systems 
Commonly used delivery platform for vaccine antigens. Antigens can be either loaded on the 
surface of the platform (Polymer, Liposome and Non-degradable particles) or inside the platform 
(ISCOM, Polymer and liposome), DNA vaccine and recombinant vial vectors also provide antigen 
expression in vivo. Adapted from [84]. 
 
1.3.1.1 DNA Vaccine 
Antigen gene delivered by DNA plasmid was first found could elicit 
immune response in vivo back in 1992 [85].  Compare to the traditional live 
attenuate vaccine, DNA vaccine is quite safe for in vivo immunization, thus has 
been used extensively for HIV-1 vaccine development (reviewed in [86]). Besides 
safety, DNA vaccine is very easy to design and manufacture, however, the 
immunogenicity of DNA vaccine is very low although both T and B cell responses 
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could be elicited (reviewed in [87]). Researchers have been using different 
delivering methods such as gene gun[88] or electroporation[89,90] to facilitate 
the gene delivery therefore enhance the immune response. Currently, the DNA 
vaccine has been used together with protein-based vaccine. The DNA prime, 
protein boost strategy is a very effective approach to induce strong B/T cell 
immune responses[91-93]. 
1.3.1.2 Recombinant viral vectors 
 Recombinant viral vectors have been used to deliver foreign genes since 
the 1970s [94]. Nowadays, these platforms have been extensively used to induce 
robust cytotoxic T lymphocyte (CTL) immune responses [95]. Famous vectors 
like adenovirus [96] and vaccinia virus [97,98] vectors are widely used for HIV-1 
antigen delivery. These recombinant viral vectors can be used to generate 
viruses in vitro, which later could be used for in vivo immunizations. Notably, the 
only positive human clinical trial RV144 used a recombinant carnarypox vector 
(ALVAC) containing HIV-1 genes [83]. In this study, the recombinant viruses 
were produced in chicken embryo fibroblasts, and they were used to prime the 
patients while AIDSVAX B/E (gp120) boosts were used later [99]. However, the 
use of the viral vector as a delivery vehicle may cause safety issues such as 
induction of an antiviral immune response [100], and depending on the vector 
used, integration of the viral DNA in chromosomal DNA could result in unwanted 
side effects [101]. 
      17 
1.3.1.3 ISCOMs 
ISCOMs are around 40 nm in diameter with a cage-like structure [102]. 
ISCOM nanostructure can be formed spontaneously when Quillaja saponins, 
cholesterol and phospholipids are mixed under controlled conditions. ISCOMs 
are well known for their adjuvant capability, along with their delivery features for 
many viral antigens including HIV-1 [103-105]. One group recently evaluated the 
effect of ISCOMs together with 11 other adjuvants in HIV-1 gp140 trimer 
immunized guinea pigs and non-human primates [106]. They found that unlike 
the oil-in-water emulsions (GLA-emulsion, Ribi, Emulsigen) that resulted in 
aggregation and disruption of antigen structural integrity, ISCOMs together with 
alum (GLA-alum, Adju-phos, Alhydrogel), TLR (GLA-aqueous, CpG, MPLA) or 
liposomes (GLA-liposomes, virosomes) preserved the trimer integrity. However, 
in term of eliciting antibody responses, ISCOMs did not demonstrate better 
results as compared to other adjuvants. 
1.3.1.4 Polymers 
Synthetic polymers like poly lactic acid (PLA) [107,108] or Poly Lactide-co-
Glycolic acid (PLGA) [109-111] are used for the development of drug and 
vaccine delivery systems because of their excellent biocompatibility and 
biodegradability. Natural polymers like chitosan, gelatin and sodium alginate are 
also frequently used for delivery purposes since they are not associated with 
toxicological problems as with synthetic polymers [112]. Chitosan is a natural 
polymer often chosen as an agent delivery platform and vaccine adjuvant [113-
115]. It is derived from de-acetylation of chitin [116], which is the structural 
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element in the exoskeleton of crustaceans (e.g. crab shells). My lab also uses 
chitosan as a vaccine delivery platform and obtains a significant immune 
response from mice, rabbits [80] and macaques (unpublished data).  
1.3.1.5 Liposomes 
Liposomes were first described in 1964 [117], and are currently widely 
applied in biomedical delivery [22,118-121]. The simplest liposome is made of 
lipid bilayers, which can carry hydrophilic molecules inside the aqueous core and 
hydrophobic molecules among the bilayers [122]. Today, liposomes have 
become a multifunctional delivery platform for a wide range of different targets 
[122]. Since the cell membrane is also made of lipid bilayers, lipid-based delivery 
platforms are very biocompatible and can easily fuse with the cell membrane to 
complete delivery. However, there are also some drawbacks, such as fast 
elimination from blood circulation, a lack of structural integrity that results in 
content leakage and instability during storage [123]. Researchers have been 
working to overcome those drawbacks with lipid-polymer hybrid nanoparticles 
[124].  
 
1.3.2 Gold Nanoparticle Delivery Platform 
Metal is one of the most used non-degradable materials for delivery 
purposes. Noble metals such as gold or sliver, or metal sulfides like AuS and 
CuS have been demonstrating great potential as nano-carriers [125]. GNPs 
among all other metal-based nano-carriers are the most popular and extensively 
explored delivery platform.  
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1.3.2.1 Synthesis of GNPs  
GNPs can be easily generated by reducing tetrachloroauric acid (HAuCl4), 
a method was first introduced in 1951 [126].  The synthesis reaction can be 
summarized as: 
2HAuCl4 + 3C6H8O7(citric acid)  2Au + 3C5H6O5(3-ketoglutaric acid) + 
8HCl + 3CO2 [127] 
The size of the gold nanoparticles can be controlled from 16 to 150 nm by 
adjusting the gold to citrate concentration ratio [128]. The citrate acts as both a 
reducing agent and stabilizer (Figure 1.7) 
 
 
Figure 1.7: Schematic presentation of preparation of citrate stabilized GNP in water 
The citrate reduces the gold salt into GNPs and then caps the surface of GNPs. Adapted from 
[129] 
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1.3.2.2 From sphere to rod  
The shape of GNPs can also be controlled.  Chen et al. [130] made five 
different GNP shapes including nano-spheres, nano-cubes, nano-branches, 
nano-rods, and nano-bipyramids using the seed-mediated growth method. 
Besides the primary spheres, gold nano-rods (GNRs) are another important 
formation for delivery. Niikura et al. [131] demonstrated that compared to spheres 
and cubes, rods were the most efficiently internalized into cells and induced the 
secretion of inflammasome related cytokines, and thus could be used as an 
effective vaccine platform. 
The most common way to produce GNRs is the seed-mediated method 
[132,133]. Cetyltrimethylammonium bromide (CTAB) is usually used as the 
capping reagent for GNRs [134] (Figure 1.8). 
 
 
Figure 1.8: Making GNRs 
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Seed-mediated growth method for making GNRs. Instead of citrate, a strong reducing agent like 
NaBH4 is used for the reduction of gold salt. Citrate or CTAB is used to cap the seed particles. 
Those seeds can grow into a larger, rod-like shape by using more gold salt, a weak reducing 
agent (usually ascorbic acid), and more CTAB (rod-like micelle template). 
 
1.3.2.3 Linking biomolecules on GNPs 
Capping ligands like citrate or CTAB serve as stabilizers for the newly 
synthesized GNPs. However, the surface ligands can be displaced by thiols 
through the ligand exchange reaction [135,136]. The strong binding of thiol to 
gold (~50 kcal/mol [137]) is the foundation to link the protein-based vaccine or 
other therapeutic molecules on GNPs for delivery. The thiol bond can be either 
provided by the protein/peptide itself or through a linker with a thiol end. Cysteine 
is the only amino acid that has a thiol group on its side chain, and it is usually 
used to link GNPs. Studies have either introduced cysteine mutations or directly 
synthesized the cysteine into the small peptides, which may not have cysteine 
naturally [138,139].   
Another way of loading antigens on GNPs is to use a linker with one thiol 
at the end. 4-aminothiolphenol (4-ATP) can be used to cap the GNP surface 
[140,141].  
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Figure 1.9: 4-ATP linker 
A schematic graph showing how to load protein antigens on GNPs through the 4-ATP linker: the 
thiol end of 4-ATP provides binding with GNPs, and the primary amine end will form an Azo bond 
with the imidazole side chain of the histidine inside the protein after sodium nitrite treatment. 
 
The thiol end of 4-ATP can attach to GNPs while the amine group can be 
modified into a diazonium group, which will form the azo bond with the aromatic 
side chain of histidine [142-144]. Since the his-tag is widely used in recombinant 
proteins and is quite easy to incorporate into protein antigens, 4-ATP has great 
potential to be used as an alternate linker. 
The most commonly used chemical to bind his-tag is the nitrilotiracetic 
acid (NTA), which is commercially available for purification of his-tagged proteins. 
Linker N-[Nα,Nα-Bis(carboxymethyl)-L-lysine]-12-mercaptododecanamide (SH-
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NTA) has both a thiol end and a NTA end, therefore, it can be a perfect linker 
between the GNPs and antigens. Additionally, the bond between NTA and 
histidine is not stable in a low pH environment, which means that after the 
protein-loaded GNPs are taken up by antigen presenting cells (APCs), the 
antigen will be released for further processing, since the acidification inside the 
endosomes can break the bond between NTA and his-tag.  
1.3.2.4 Biocompatibility and in vivo delivery 
 Mammalian cells can easily take up GNPs. Chithrani et al. [145] tested 
the uptake efficiency of different sizes and shapes of GNPs using Hela cells. 
They found the cells could most efficiently take up spherical GNPs with 
diameters of 50nm, reaching 6*103 particles in one cell within 6 hrs. In another 
study [146], these researchers revealed the mechanism of cell entrance is via the 
receptor-mediated endocytosis pathway (RME). In this pathway, the ligand on a 
surface coated protein binds onto a receptor on the cell surface, and then the cell 
will engulf the whole GNP through endocytosis. Besides high tissue permeability 
without hampering cell functionality, GNPs are also well known for their 
biocompatibility, such as non-toxicity and non-immunogenicity to mammalian 
cells [147]. In vitro studies have shown that, in varying sizes, gold spheres [148] 
and gold rods [149] are non-toxic to mammalian cells even at very high 
concentrations (150~250µM, around 1010 particles/ml). Chen et al. [150] 
performed further toxicity tests in vivo using BALB/c mice. They tested GNPs of 
varying diameters. The mice were injected intraperitoneally (IP) at a dose of 8 
mg/kg/week (four times more than the dosage used for mice immunization in 
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Chapter 3). Their results showed that GNPs with sizes of 3, 5, 50, and 100nm 
were safe through the experimental period (more than 50 days). However, mice 
injected with other sizes (8, 12, 17 and 38 nm) exhibited symptoms of toxicity, 
and the length of time until half mortality was 21 days. They also found that 
coating the toxic GNPs (e.g. 17nm) with protein antigens could prolong lifespan 
to more than 50 days. Along with the reduction of toxicity, strong antibody 
responses were induced.  
The bio-distribution of GNPs following administration has also been 
analyzed. De Jong et al. [151] examined the bio-distribution of GNPs of varying 
sizes in rats 24 hours after intravenous administration. They found the 10nm 
particles had spread into many different systems such as the blood, liver, spleen, 
kidney, heart, lung and brain. In contrast, the 50nm and larger particles were only 
detected in the blood, liver and spleen. Elsewhere, it has been shown that GNPs 
smaller than 20nm can cross the blood-brain barrier (BBB) [152] and the blood-
retinal barrier (BRB) [153] for therapeutic applications. Simpson et al. [154] 
monitored the bio-distribution of glutathione coated GNPs (~2nm) in mice for 6 
weeks. They found that 30% of the GNPs were excreted though the renal system 
within one hour, and 80% of what remained was voided within hours. The 
distribution pattern for what remained was correlated with the injection dose, and 
the kidneys, spleen and liver were the main organs that accumulated GNPs. 
Those GNPs located in the liver and spleen were excreted after 3 to 4 months 
[155]. Most of these particles can be excreted through the hepato-biliary or renal 
clearance [156,157]. 
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1.3.2.5 Applications for vaccine delivery 
GNPs have been widely used in vaccine development as a delivery 
platform to boost both B cell and T cell responses [158]. This platform has been 
used against many bacteria pathogens including Escherichia coli (E. coli) [159], 
Listeria moncytogenes (listeria) [160], Burkholderia mallei (causative agent of 
glanders) [161,162], and Clostridium tetani (causative agent of tetanus) [163] to 
induce higher antibody titers as compared to other platforms or no platforms, as 
well as to help elicit many T cell activation cytokines including interferon gamma 
(INFγ) and interleukin-17 (IL-17).  
GNPs can also target many viruses. Chen et al. [138] investigated the 
antibody response elicited in mice by a synthetic peptide, which resembles a 
foot-and mouth disease virus (FMDV) protein, loaded on GNPs of different sizes. 
They found that 8nm GNPs elicited the highest antibody titer (6x104) at week 6, 
which is three times higher than the keyhole limpet hemocyanin (KLH) platform 
when tested under parallel conditions. Furthermore, GNPs did not induce any 
detectable immune response against the platform, while KLH induced a strong 
antibody response against itself, which was even higher than the response 
against the loaded antigen. Niikura et al. [131] also evaluated the immune 
responses of the West Nile virus (WNV) envelope protein loaded on GNPs of 
different sizes and shapes. Compared to cube (40x40x40 nm) and rod 
(40x10nm) shapes, they found that the 40nm spherical GNPs elicited the highest 
immune response in mice. Their in vitro study revealed that rods could induce 
inflammasome-related cytokines such as IL-1β and IL-18, while spheres and 
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cubes induced the pro-inflammatory cytokines such as TNF-α, IL-6, IL-12 and 
GM-CSF. The high antibody production was speculated to correlate with these 
inflammatory cytokines, whereas rods acted via the inflammasome activation. 
There are also reports using GNPs to carry anti-HIV drugs [164-166]; however, 
the application of GNPs in HIV-1 vaccines is limited. One group used GNPs to 
deliver a DNA-based vaccine against HIV-1 [167]. They modified the surface of 
GNRs with three different chemicals to load HIV-1 Env plasmid DNA for 
vaccination in mice: CTAB, poly (diallydimethylammonium chloride) (PDDAC), 
and polyethyleneimine (PEI). Compared to the naked DNA plasmid, the PDDAC 
or PEI modified GNRs significantly promoted both humoral and cellular immunity. 
Apart from this study, we are not aware of any literature discussing the delivery 
of protein-based antigens for HIV-1 vaccine study.  
To apply this novel platform in HIV-1 subunit vaccine development, we 
started the original research first in gp41-based antigens by loading directly on 
GNPs though the introduced cysteine mutations (Chapter 2). By introducing 
cysteine at different part of the antigen, we tend to obtain different antigen 
orientations on the GNP surface to better present the critical epitopes. The result 
indicated that a linker might be helpful to improve the antibody response rather 
than direct linking. Therefore, we further performed a study for a gp120-based 
antigen delivered on GNPs using the SH-NTA linker (Chapter 3). Strong antibody 
responses were elicited in both mice and rabbits. We also obtained neutralizing 
activity in the rabbit sera. Additionally, there is also an immune response 
assessment in mice by using the GNR-4ATP delivery platform (Appendix). 
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2.1 Abstract 
Inducing a high neutralizing antibody response is of crucial importance for 
the success of a subunit vaccine. In this study, we utilized gold nanoparticles 
(GNPs) to deliver HIV-1 gp41-based antigens, hypothesizing this platform could 
enhance the observed immune response as well as present the critical epitopes 
to immune cells. To link the antigen to the GNP, we first introduced a cysteine 
mutation at either terminal. Both variants elicited strong immune responses in 
rabbits, but no neutralizing antibodies were elicited. Next we introduced three 
separate internal cysteine mutations to block a nearby immune-dominant region 
by steric hindrance via protein-GNP attachment. In contrast to our first results, 
the immune responses from these variants were very low when compared to the 
original terminal variants. This study indicates that the location of antigen-GNP 
linkage might be critical to elicit high immune response and provides insights for 
vaccine development using GNPs as a vaccine delivery platform.  
 
2.2 Introduction 
Choosing a proper antigen delivery platform is essential for the success of a 
vaccine [168]. Gold nanoparticles (GNPs) have been used as non-toxic carriers 
for drug and gene delivery applications [169-171], and more recently have also 
been applied as a platform to deliver vaccines [131,138]. Studies have shown 
that GNPs can greatly improve the immune response of an attached antigen 
[158] without producing detectable toxicity and physiological damage [154,172]. 
Additionally, the self-assembly reaction of organo-thiol compounds onto the gold 
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surface allows covalent linkage of antigens containing cysteine with a free thiol to 
GNP without having to use harsh chemicals that could potentially alter epitope 
structure [173]. We are unaware of any other groups using GNPs to deliver a 
HIV-based subunit immunogen, so it is important to test this novel delivery 
platform for this purpose.  
When using antigen delivery platforms, the attached antigen must still 
interact well with the B cell receptors [174]. We speculated that exposing the 
broadly neutralizing antibodies (bnAbs) epitopes in the antigen on delivery 
platform could facilitate this interaction. Because these epitopes are known, our 
strategy is to generate GNP bound antigens, which present the bnAbs epitopes 
to immune cells. Those epitopes suitable for B cell activation are located on the 
envelope glycoprotein of HIV [47]. The two HIV glycoproteins are gp120 and 
gp41 [175]. A small, highly conserved domain located in gp41, the membrane 
proximal external region (MPER) [176], is targeted by four previously isolated 
bnAbs; namely, 2F5 [177-179], 4E10 [180], Z13e1 [63,65], and 10E8 [66]. Thus, 
this region is an attractive target for HIV vaccine development.  
However, short MPER-based peptides are weakly immunogenic 
[176,181,182], thus requiring potent adjuvants or delivery platforms to increase 
their immunogenicity. Additionally, optimizing the presentation of the MPER may 
also be crucial for eliciting nAbs with potencies equal to or exceeding those of 
currently isolated ones [65,183]. Thus, a delivery platform, which could adopt 
different MPER orientations on its surface, could be helpful to present the critical 
epitopes, depending on how the antigen is attached on the platform.  
      30 
GNPs present many benefits as vaccine carriers by serving as delivery 
systems that facilitate targeting to antigen-presenting cells and induce strong 
immune responses [84]. Thus, we hypothesized that GNPs could enhance the 
effectiveness of MPER-based antigens as well as present the critical MPER 
epitope to the immune system. We therefore designed several gp41-derived 
antigens capable of using GNPs as the delivery platform.  
 
2.3 Results 
2.3.1 Construction of The Terminal Cysteine Variants 
The original antigen gp41-54Q contained the gp41 heptad repeat 2 (HR2) 
and MPER. To link this gp41-based antigen on GNPs, we introduced cysteine 
mutation in the constructs through site-directed mutagenesis. Mutations were first 
introduced in the original antigen at the N or C terminus to ensure peptide 
conjugation to GNPs (Figure 2.1, A). Highly pure proteins were obtained (Figure 
2.1, B). The purified proteins are around 9kDa. 
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Figure 2.1: Schematic diagram, construct sequence, and purification of the cysteine 
variants.   
(A) Construct map for the cysteine variants. The T7 protein expression tag is removed from the 
54QC and C54Q constructs after protein purification by trypsin. HR2 and MPER from HIV-1 gp41 
are the main antigen parts. The C-terminal his-tag is used for protein purification. (B) Purified 
12C, 19C, 26C, 54QC and C54Q on SDS-PAGE.  
 
2.3.2 Terminal Variants Loading on GNPs 
We tested whether the cysteine variants could bind the GNPs. The newly 
introduced cysteine residue can provide a sulfhydryl group as a conjugating site 
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for attachment to the GNPs. Conjugation of cysteine variants to GNPs was 
optimized by adding different concentrations of the antigens to 1 ml suspensions 
of 50 nm GNPs (4.5x1010 particles). For all the cysteine variants, 8 µg was the 
maximum amount that could be loaded onto 1 ml suspension of the 50 nm 
GNPs, which means around 104 antigen molecules, can be loaded on a single 
GNP. Conjugations of cysteine variants to GNPs were analyzed by 0.8% agarose 
gel electrophoresis. GNPs alone do not move in the agarose gel, but after protein 
binding, they are negatively charged and can migrate (Figure 2.2, A).  
 
 
Figure 2.2: Characterization of antigens loading onto GNPs  
(A) Agarose gel analysis of the terminal cysteine variants 54QC and C54Q, The right gel is the 
same gel stained with Coomassie Blue. (B) Gel analysis done for the internal cysteine variants 
12C, 19C and 26C. 
 
      33 
2.3.3 Antigenicity Test of The Terminal Variants 
An ELISA test was done to determine if the bnAb epitope in the MPER 
region is still exposed when the variants are bound to GNPs (Figure 2.3). 
Compared to the ELISA results from the free antigen coated plates, the results 
from the GNP ELISA indicate that C54Q and 54QC could still be strongly 
recognized by 2F5 even after loaded on GNPs. However, the binding with 4E10 
and Z13e1 were significantly reduced after loading antigens on the GNPs. We 
did not include 10E8, because the K683Q mutation disrupts a crucial amino acid 
for 10E8 binding. 
 
 
Figure 2.3: Antigenic properties of 54QC and C54Q.  
(A-C) Antibodies recognition of the free antigens (D-F) Same analysis for the cysteine variants 
loaded on GNPs 
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2.3.4 Immunization Study of The Terminal Variants 
To assess the immunogenicity of C54Q and 54QC, two groups of three 
rabbits each were immunized with either antigen loaded onto 50 nm GNPs. Sera 
were drawn two weeks after each immunization, and antibody titer was 
determined using ELISA (Figure 2.4). A low antibody titer of around 103 was 
recorded after the first immunization in both groups. The antibody response 
continued to increase significantly after the second and third immunizations. 
Rabbits immunized with 54QC induced antibody titers up to 106. Rabbits 
immunized with C54Q induced slightly lower antibody titers, which were less than 
106. Overall, no major differences in antibody titers were seen among rabbits 
within each group (unpaired t test, P=0.37). To determine whether antibodies 
against GNPs were elicited, ELISA was done with just GNPs as a coating 
antigen. No antibody response specific to the GNPs was elicited. 
 
 
Figure 2.4: Immunogenicity of 54QC and C54Q immunized rabbits.  
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(A) End-point antibody titers of 54QC in immunized rabbits measured by ELISA. Sera from pre-
immune (pre) and those collected two weeks after 1st, 2nd, 3rd, and 4th immunization were 
analyzed. (B) Same analysis for C54Q. Rabbit numbers are indicated by R1, R2 and R3. 
 
2.3.5 Epitope Mapping of The Terminal Variants 
Since no neutralizing activity was detected in the rabbit sera from these 
two terminal variants, we want to determine from which regions of 54QC and 
C54Q the antibodies were raised. The peptide ELISA test with overlapping 
biotinylated peptides (10-mer) was then performed. The majority of the antibody 
responses were targeting linear epitopes within the HR2 region (Figure 2.5). 
Specifically, antibodies from all rabbits recognized peptides 638 to 656, with the 
peptide 641 inducing the highest immune response. This region has been 
classified as the non-neutralizing cluster II immune-dominant region [184], while 
the neutralizing epitopes of gp41 are located in the MPER region (peptide 659 to 
674) [185], which is at the C terminal end of our antigens.   
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Figure 2.5: Identification of immunogenic linear epitopes.  
(A) ELISA was performed using 10-mer biotinylated overlapping peptides that cover the entire 
length of gp41-54Q. On the top panel, the data is for 54QC-immunized rabbits, and the bottom 
panel shows the data for C54Q immunized rabbits. Data points represent serum samples (1:100 
dilution) from the three rabbits collected two weeks after the fourth immunization. (B) List of 
immunogenic linear peptides epitopes. 
 
2.3.6 Introducing The Internal Cysteine Variants 
To direct the immune response away from the non-neutralizing epitopes 
and towards the neutralizing epitopes found in the MPER, we tried to minimize 
immune responses toward non-neutralizing epitopes present in the HR2 by using 
steric hindrance introduced by GNPs surface linkage. We therefore made three 
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more variants containing a cysteine mutation inside the HR2 domain to replace 
the amino acids L12, E19 and K26 (counted from the beginning of HR2) to make 
the 12C, 19C and 26C variants (Figure 2.1, A). Because cysteine can directly 
bind to the surface of GNPs, the opposite protein side should be exposed to the 
immune system. We hypothesized that attaching the protein through the non-
neutralizing immune-dominant region to the GNPs could block immune 
responses to this region and better expose the MPER neutralizing epitopes after 
GNP loading. 
 
2.3.7 Internal Variants Loading on GNPs 
We can see internal variants can also bind well on GNPs (Figure 2.2, B). 
The variants’ different speeds on the agarose gel is most likely due to their 
charge difference in the running buffer. For 19C, the original negatively charged 
glutamic acid was replaced by the neutral cysteine, so 19C had a slower 
migration than 12C. On the contrary, in 26C, the original amino acid lysine was 
positively charged, which resulted in a faster migration than 12C.  
 
2.3.8 Antigenicity Test of The Internal Variants 
The internal variants could bind to 2F5 as strongly as the original two 
terminal variants. And for 4E10, unlike the terminal variants, even after loaded on 
GNPs, these internal variants still showed similar binding patterns with the free 
antigens. Even for Z13e1, while the gold-loaded internal variants also showed 
weaker binding than the free antigens, their binding signals were still higher than 
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the gold-loaded terminal variants  (Figure 2.3 and Figure 2.6). These results may 
indicate that the epitopes on MPER have the potential for better exposure when 
alternate GNP attachment sites are introduced. Additionally, 4E10 has a much 
higher signal than Z13e1, which suggests the C-terminal of the antigens are well 
exposed on GNPs, as the 4E10 epitope is at the very C-terminal end while 
Z13e1 is more inside. 
 
 
Figure 2.6: Antigenic properties of 12C, 19C and 26C. 
(A-C) Antibodies recognition of the free antigens (D-F) Same analysis for the cysteine variants 
loaded on GNPs 
 
2.3.9 Immunization Study of Internal Variants 
We immunized additional rabbits using the 12C, 19C and 26C constructs, 
hypothesizing that the internal mutation would block antibody responses against 
undesired epitopes and redirect immune responses toward the more desirable 
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bnAb epitopes in peptides 665 (2F5) and 671 (4E10 and Z13e1) [186]. Three 
groups of two rabbits each were immunized with the cysteine variants bound to 
50 nm GNPs. Surprisingly, the immune responses elicited by 12C, 19C and 26C 
were very low (most up to 103, Figure 2.7, A-C), compared to that of 54QC and 
C54Q (Figure 2.4). Additionally, the peptide ELISA did not detect antibody 
responses directed toward the MPER (data not shown). However, for another 
variant 28C (E657C), we found higher antibody responses (up to 105) after the 
3rd immunization using Zinc chitosan (ZNC) instead of GNPs (data not shown). 
We suspected that the very low antibody response was more likely due to 
the close binding of the internal region of the antigen onto the GNPs rather than 
the influence brought by the mutation itself. Because even if the cysteine 
mutation incorporated within the antigen disturbed the T helper cell epitope, the 
antibody response should not be severely reduced, since multivalent 
presentation of antigens can activate B cell through the T cell independent 
pathway [187,188]. To test our hypothesis, we immunized rabbits with the 
alternate ZNC adjuvant. As the antigens bind ZNC through their C-terminal 
6xHis-tag, we hypothesized that these variants would now have a conformation 
similar to 54QC bound to GNP. This time, we elicited a stronger immune 
response, with most reaching up to 105 (Figure 2.7, D-F), which suggested the 
mutations inside may not harm the antibody response, but the way of binding the 
antigen on the platform could affect the response greatly. And again, neutralizing 
activity was not detected in any of the sera samples (data not shown)  
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Figure 2.7: Immunogenicity of 12C, 19C and 26C immunized rabbits  
(A-C) ELISA end point titer of cysteine mutants immunized using GNPs as delivery platform.  
(D-F) Same analysis for the internal cysteine variants immunized with ZNC. 
 
2.4 Discussion 
Recently, many studies have focused their research on the optimization of 
delivery platforms for vaccines to enhance their efficiency [124,131,163,173,189]. 
Gold nanoparticles are certainly a strong potential platform. There are also 
reports showing that using GNPs can achieve higher titer compared to using 
other adjuvants [138,158,172,190]. The objective of this study was to test the 
immunogenicity of our M group consensus sequence based gp41-54Q antigen 
(unpublished data) by using a GNP delivery platform to conjugate antigens in a 
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site-directed manner while maintaining their conformation. To this end, we initially 
constructed variants 54QC and C54Q, which includes a N-terminal or C-terminal 
cysteine for site-directed GNPs attachment.   
Although we obtained antibody titers up to 106, we did not observe 
neutralizing activity in the sera of immunized rabbits. Interestingly, the immune 
responses were mostly targeting outside the MPER and towards non-neutralizing 
epitopes condensed in the HR2 area. However, we did see strong 2F5 binding of 
54QC and C54Q even after loading GNPs, which indicate that after GNP 
attachment, the variants still retain the functional conformation required for 
presenting the epitope for 2F5. Nevertheless, we did not observe strong binding 
of the 4E10 and Z13e1 with these two antigens on GNP. Therefore, the reason 
why all the antibody responses are diverted to HR2 could indicate that the 
immuno-dominant epitope in the HR2 region may misdirect the immune system 
response away from the neutralizing epitope. One possibility, specific to 54QC, is 
that the 4E10 and Z13e1 epitopes are close to the GNP and thus less accessible 
to antibody binding. This, however, does not explain the same observance with 
C54Q, as the region that contains the bnAbs epitopes should be well exposed. It 
is possible that the 6xHis-tag, which is known to adsorb on gold [191-193], may 
have also bound the GNPs. Therefore, with two ends of the antigen binding on 
GNP, the bending antigen would most likely not present the bnAb epitopes well 
because of their proximity to the surface of GNPs.  
Based on the data of the epitope mapping of 54QC and C54Q immunized 
rabbits sera (Figure 2.5), we attempted to expose the bnAb epitopes and 
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disguise the non-neutralizing epitopes by linking the antigens on the GNPs 
through the HR2 region. However, the whole antibody responses for these 
internal cysteine variants were considerably lower than our earlier tests. Besides, 
the antibody responses were low against all the 10-mer peptides covering the 
HR2 and MPER in gp41 with no sign of immune focusing in the MPER (data not 
shown). Nevertheless, all rabbits induced a better immune response against the 
internal cysteine variants when paired with ZNC rather than GNPs, indicating that 
the very low antibody titers may have resulted from how the antigens were 
conjugated or oriented on the surface of the GNPs. Although the way these 
internal cysteine variants could bind on the ZNC through the C-terminal his-tag is 
quite similar to the way 54QC bind on GNPs through the C-terminal cysteine, 
their antibody titers using the ZNC were still lower than that of 54QC on GNPs. 
This small difference in antibody titers was probably because of the effect of 
GNPs, which can elicit a higher immune response [138,158,172,190]. 
Additionally, the cysteine replacement of the internal amino acid might change 
the antigen conformation, which could also affect the immune response. 
However, we want to emphasize here, even these two factors could result a 
lower antibody response of those internal cysteine variants on ZNC than 54QC 
on GNP, we still obtained much higher titer than these variants on GNP, which 
suggested that the linking site on the antigen to GNP might be of crucial 
importance to affect the antibody response.  
From the results of the antigenicity tests, we know that when using GNPs 
as the delivery platform, introducing cysteine inside of the antigen assists MPER 
      43 
epitopes exposing in vitro. However, the in vivo immunization studies gave us the 
opposite result; internal insertions of cysteine did not provide neutralizing activity 
but blocked overall immune response. Our hypothesis is that the steric hindrance 
prevented effective protease cleavage within antigen-presenting cells. The 
immune system exposure of the internal cysteine variants may have been 
drastically impaired because the proteinase cleavage site was located too close 
to the GNPs’ surface. Thus, they may have been poorly accessible to the 
proteinase, which ultimately resulted in less overall epitope exposure and lower 
overall antibody titers. 
These results indicate that the problem might not be the immunogenicity 
of the variants but perhaps how they were conjugated or oriented on the surface 
of the GNPs. These experiments highlight the need for a linker to better expose 
antigens and epitopes of interests. Therefore, while choosing the appropriate 
antigen delivery platform is important, the placement of antigen to platform 
linkage is also crucial. Eliciting a higher immune response may require a spacer 
between the antigen and the GNPs. To this end, we are developing a new 
construct that includes this modification to better expose the antigen to the 
immune cells and enhance responses. 
 
2.5 Materials and Methods 
2.5.1 Construction of Cysteine Variants 
We introduced five cysteine variants to the original gp41-based antigen, 
gp41-54Q (unpublished data), which encode 54 amino acids of the HR2 and 
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MPER of HIV-1 gp41 (based on MCON6 sequence [194]) (Figure 2.1). Two 
contained mutations at the C-terminal and N-terminal ends, called 54QC and 
C54Q, respectively. The other three constructs (12C, 19C, and 26C) contain 
internal gp41-54Q mutations at the indicated positions. Cysteine mutations were 
introduced to the pUC57 vector by site directed mutagenesis using the 
QuickChange XL II Site-Directed Mutagenesis Kit (Agilent). Primers for the 
cysteine variants were designed using the QuickChange Primer Design 
Application. Primer pairs are shown in table 2.1.  
 
Table 2.1: Primer sets for the cysteine variants 
Variant 
names 
Sense Anti-sense 
54QC 5'-gcaaatgggtcgctgcggatccgagtggg-3' 5'-cccactcggatccgcagcgacccatttgc-3' 
C54Q 5’-catcaccatcatcaccattgctaagaattcgagct 
ccgt-3’ 
5’-acggagctcgaattcttagcaatggtgatgatggt 
gatg-3’ 
12C 5'-tctccaactacaccgactgcatctaccgcctgatc 
g-3’ 
5'-cgatcaggcggtagatgcagtcggtgtagttggag 
a-3’ 
19C 5'-ctaccgcctgatcgagtgctcccagaaccagca 
gg-3' 
5'-cctgctggttctgggagcactcgatcaggcggtag-
3’ 
26C 5'-ccagaaccagcaggagtgcaacgagcaggag 
ctgc-3' 
5'-gcagctcctgctcgttgcactcctgctggttctgg-3’ 
 
PCR was performed at 95°C for 1 min for the initial denaturation, followed 
by 18 cycles of 95°C for 50 s, 60°C for 50 s, and 68°C for 6 min, with a final 
extension step at 68°C for 7 min. 1 µl of DpnI was added to the application 
reaction and incubated at 37 °C for another 1hr; products were then transformed 
into XL-10 Gold competent cells to obtain the final variant constructs. BamHI and 
EcoRI were used as the digestion site to insert the constructs into pET-21a. All 
constructs were confirmed by DNA sequencing. 
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2.5.2 Expression and Purification of Cysteine Variants 
Expression and purification of the variants were performed based on the 
method from Penn-Nicholson et al. [195] with a few modifications. For the 
expression of cysteine variants, the plasmid transformed E. coli T7 Express 
IysY/Iq (NEB) was cultured to OD600=1.0 at 37oC. 1 mM isopropyl-beta-D-
thiogalactopyranoside (IPTG) was added in to the culture till OD600 reached 5.0 
at 31oC. The bacteria pellet was span down by centrifugation at 5000 rpm for 20 
min and washed in PBS (pH 7.4) and then lysed through sonication with Branson 
Digital Sonifier. The sonicated sample was centrifuged at 10,000 rpm for 20 min. 
And the pellet went through sonication for two more times, before we dissolve the 
inclusion bodies in the pellet in 8 M urea (PBS, pH 7.4). After removing the 
Insoluble debris by centrifugation at 10,000 rpm for 20 min, Ni-NTA resin 
(QIAGEN) was added into the soluble supernatant and mixing on a shaker 
overnight at 4°C. The whole mixture was loaded into a column, and the bound 
protein was re-natured through slow washing the column with decreased 
concentration of urea (8 M, 6 M, 4 M, 3 M, 2 M, 1 M, and 0 M). The column was 
then washed by 20 mM imidazole in PBS, and eluted with 250 mM imidazole in 
PBS. The final protein product was dialyzed in PBS (pH 8). 
 
2.5.3 Loading Cysteine Variants onto 50 nm GNPs 
50 nm GNPs were purchased from NANOCSTM. Conjugation of cysteine 
variants to 50 nm GNPs was performed according to the method of Chen et al. 
[138]. Antigen-GNP conjugation was achieved by titrating the antigens into a 
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GNP’s suspension. After reaching the saturation point, the antigen-GNP 
complexes were pelleted by centrifugation at 6000×g for 60 min at 4°C, and the 
supernatant was removed and saved for protein analysis. The antigen-GNP 
pellet was then re-suspended in PBS and used for rabbit immunization. The 
amount of antigen loaded onto GNPs was calculated as the amount of antigen 
initially added minus the amount of antigen in the supernatant after 
centrifugation.  
 
2.5.4 Gel Electrophoresis 
Gel analysis was done according to the method from Chen et al. [138] with 
slight modifications. The antigen-GNP pellet was re-suspended in 10 µl of 1% 
tris-buffered saline (TBS) and loaded onto a 0.8% agarose gel. Gel separation 
was performed using an electrophoresis unit running at 80 V for 1 hr at room 
temperature. Gels were stained with 0.5% Coomassie Brilliant Blue R-250 in 
50% methanol and 10% acetic acid and destained in 40 % methanol and 10 % 
acetic acid to view the protein bands. 
 
2.5.5 Rabbit Immunization  
New Zealand white female rabbits (2 kg) were purchased from Charles 
River (USA) and housed under specific-pathogen-free environments following the 
animal protocol guidelines of the Committee on Animal Care of Iowa State 
University. For 54QC and C54Q we subcutaneously immunized 3 rabbits each 
on weeks 0, 4, 9 and 15. For 12C, 19C and 26C, we immunized 2 rabbits each 
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on weeks 0, 4, 9 loaded on GNPs and 13, 17, 22 loaded on ZNC. The 
immunizations were performed with a dose of 50µg for antigens loaded on GNPs 
and 200µg for antigens loaded on ZNC per immunization, and blood was 
collected 2 weeks after each immunization.  
 
2.5.6 Enzyme-linked Immunosorbent Assay (ELISA) 
Blood was drawn from the central ear artery at two weeks after each 
injection, and antibody titer was determined using ELISA. Briefly, 30 ng of 
cysteine variants protein were added onto each well of the 96-well Nunc-Immuno 
Plates in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6) 
overnight at 4 oC. 200 μl of blocking buffer containing 2.5% skim milk and 5% calf 
serum in PBS was added into each well and incubated at 37 oC for 1hr to block 
the non-specific binding of antibodies, and the plates were washed 5 times with 
0.1% Tween 20 in PBS. Rabbit serum (anti-cysteine variant) was diluted 1:1000 
in blocking buffer, and 100 μl of serial 3-fold dilutions were added to each well 
and incubated for 2 hrs at 37 oC. Wells were washed five times, and horseradish 
peroxidase (HRP)-linked secondary antibody (goat anti-rabbit, 1:3000 dilution) 
(Thermo Scientific; Cat #31430) was added to each well and incubated (100 µl, 1 
hr at 37 oC). Each well was washed five times before adding 100 µl of TMB HRP-
substrate (Bio-Rad) for 10 min developing. 50 µl of 2 N H2SO4 was then added to 
each well to stop the reaction. The 450 nm value was read on a microplate 
reader (Versamax by Molecular Devices). Experiments were performed in 
duplicate. 
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2.5.7 GNP ELISA  
Also to determine if GNP-bound cysteine variants were recognized by 
2F5, 4E10, and Z13, ELISA was done mainly according to the methods of Chen 
et al [138]. Briefly, to coat plates with protein loaded GNPs, each well was 
pretreated with 200 μl of 1 mM 3-aminopropyl-triethoxysilane (APTES) in ethanol 
at room temperature for 40 min. According to the authors, APTES encourages 
optimal crosslinking of GNPs to plastic wells, allowing an effective ELISA to be 
conducted. The activated wells were washed with ethanol twice, followed by 
distilled water twice. Antigen-loaded GNPs were coated at 30ng/well onto 96-well 
Nunc-Immuno plates using a coating buffer (150mM Na2CO3, 350mM NaHCO3, 
30 mM NaN3, pH9.6), and they were incubated at room temperature for 2 hrs. 
This was followed by three distilled water washes and three washes with 0.5% 
Triton X-100 in PBS. The assay proceeded with the conventional ELISA steps as 
above. Human monoclonal antibodies (2F5 [177-179], 4E10 [180] and Z13e1 
[63,65]  and goat anti-human (Thermo-Scientific; Cat# 31430) were used as 
primary and secondary antibodies respectively.  
 
2.5.8 Peptide ELISA 
Peptide ELISA with overlapping biotinylated peptides (10-mer, mixture of 
both N and C terminally biotinylated peptides) was also performed as described, 
except that 10-mer peptides (200 ng/well, 100 ng of N terminal plus 100 ng C 
terminal biotinylated peptides) covering the entire length of the original gp41-54Q 
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antigen were coated onto a streptavidin-coated plate instead of the whole 
antigens. The rest of the test followed conventional ELISA steps as previously 
outlined. 
 
2.5.9 Neutralization Assays 
Single round HIV-1 pseudovirus infection assays in TZM-bl cells were 
measured by a luciferase-based assay as previously described [196,197]. Briefly, 
heat inactivated (56°C for 1h) rabbit sera were diluted in Dulbecco’s modified 
Eagle’s medium (DMEM) with 10% heat inactivated FBS and incubated for 1 hr 
in the presence of 200 50% tissue culture infective doses (TCID50) of virus at 
37°C.  1*104 TZM-bl cells were then added into the mixtures with DEAE-dextran 
(Sigma) added at a final concentration of 10 µg/ml.  Plates were incubated at 
37°C for 48 hrs, developed with Bright-Glo Luciferase (Promega, Madison, WI) 
and analyzed for luciferase activity using a luminometer (Synergy 2, 
BioTek).  The 50% inhibitory dose (ID50) or concentration (IC50) was defined as 
either the sera dilution or purified IgG concentration at which relative 
luminescence units (RLU) were reduced 50% compared to virus control wells 
after subtraction of background RLU in cell control wells. 
Viruses tested were SF162 (tier 1A, clade B), MW965.26 (tier 1A, clade 
C), and MN.3  (tier 1A, clade B). Murine leukemia virus Env plasmid was used as 
a negative control. Sera were heat inactivated (60 min, 56°C) before use. 
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3.1 Abstract 
Inducing high titers of broadly neutralizing antibodies (bnAbs) against HIV-
1 is a critical step towards developing a protective vaccine against the virus. 
Although subunit protein immunizations can induce high antibody titers, they 
often utilize lipid-based adjuvants that could potentially denature protein 
immunogens, which would likely result in the loss of conformational epitope 
structures targeted by bnAbs. Hence, development of an antigen delivery 
platform that could induce strong antibody responses without using lipid-based 
adjuvants is much needed. In this study, we describe the establishment of an 
antigen delivery platform based on gold nanoparticles (GNP) that uses N-[Nα,Nα-
Bis(carboxymethyl)-L-lysine]-12-mercaptododecanamide for loading any proteins 
with a 6xHis tag.  This antigen loading strategy was used for efficient release of 
antigens in endosomes upon acidification, which would facilitate antigen 
processing and presentation. Our platform allows display of polyvalent forms of 
antigens for efficient B cell receptor crosslinking and B cell activation. 
Furthermore, the platform is modular and could allow the use of different 
antigens as well as co-stimulatory molecules. To demonstrate its potential, 
gp120-ODx3 was used as a model antigen that consists of three tandem repeats 
of the HIV-1 gp120 outer domain. The antigenic properties of the protein bound 
to GNP were well preserved.  The protein was highly immunogenic in both mice 
and rabbits, inducing antibody titers up to 107 after three immunizations without 
any adjuvants. Neutralizing assays demonstrated induction of nAbs against tier 1 
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HIV-1 isolates from multiple clades. Results thus far demonstrate that our GNP-
based antigen delivery platform has great potential. 
 
3.2 Introduction 
An effective HIV-1 vaccine that can stop the AIDS pandemic has yet to be 
developed. While many efforts have been made in developing immunogens, 
many researchers are working towards the development of a delivery platform 
that will enhance the effectiveness of the vaccine candidates as well [163,198-
201]. GNPs are one of the most popular delivery platforms. They have been 
widely used and studied in different areas like bio-imaging [202], biosensor [203], 
and delivery platform for drugs [204-208] and vaccines [131,161,167,209].  
The GNP delivery platform can present the antigen to the immune system 
in a multivalent manner, which has the potential to greatly enhance immune 
response [173,210,211]. GNPs can attach to the antigen either directly or with a 
linker.  For small peptide antigens, the best way to link the antigen to GNPs is 
through a cysteine amino acid [212,213]. An introduced linker can also be used 
to attach the target antigen onto the GNPs [161,207,208,214,215].  In this paper 
we chose to study the linker SH-NTA. 
When nitrilotriacetic acid (NTA) is coupled with a metal ion (Co2+, Ni2+, 
Cu2+, Zn2+), it has high affinity to the histidine imidazole ring [216]. Therefore, Ni-
NTA resin/columns have been widely used for his-tagged protein purification. 
The NTA linker on GNP can also be useful in labeling [217,218] different his-
tagged proteins. In the early 1990s, Hainfeld et al. [219] used a similar linker, 
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NTA-dipeptide-thiol, for a His-tagged adenovirus “knob” protein on 1.8 nm GNP 
as a probe for cell receptors. Later, Brinas et al. [220] tried to apply the same 
NTA linker on size–controlled GNPs (2 to 6 nm). Cho et al. [221] used MutS on a 
Ni-NTA coated gold electrode to detect the DNA mismatches. NTA linkers can 
also be used to bind an enzyme on the gold surface. SH-NTA linker [222] is used 
to bind the silicatein on the gold surface without disturbing its biocatalytic activity. 
Nakamura et al. [223] used three different NTA linkers to immobilize his-tagged 
endoglucanase on the gold surface, the enzyme still retained its inherent 
hydrolytic activity. Although the NTA linker has many different uses and 
applications, we are unaware of any publication that has the NTA linker on GNPs 
to deliver vaccines.  
We choose Cu2+ over other metal ions, like the Ni2+, because it will couple 
to NTA in a more stable manner [224], and it has stronger binding with the 
protein antigens [225] on GNPs. Thus, in our linker system, the thiol group of the 
SH-NTA is bound at one end to the GNP, while the other end has the NTA, which 
can bind to the histidine in the protein antigen. The thiol-gold bond is very strong, 
on the order of 50 kcal/mol [137], while the bind between Cu-NTA and histidine 
will break under acidic conditions (Figure 3.1). Therefore, after the antigen-
presenting cell (APC) has taken up the GNPs, the protein antigens on the GNP 
surface will be released in the endosome. This allows the proteinase to easily 
degrade the antigen for later processing.  
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Figure 3.1: Proposed mechanism of antigen delivery in vivo through GNPs 
The antigen loaded GNPs can be engulfed by APC. Inside the endosome of APC, the pH in the 
environment will reduce, which will then facilitate the breakage of the binding between the protein 
antigens with the GNPs. The released antigens are subjected for down-stream processing of the 
immune cells.   
 
Previously, we reported using a protein-based antigen derived from gp120 
outer domain (OD) as a vaccine candidate [80]. In that study, we found that 
ODx3 is potentially better than gp120. Since we are unaware of any studies 
using GNPs to deliver a HIV-based subunit immunogen, it is important to test this 
novel delivery platform for this purpose. We use SH-NTA as a linker to bridge the 
GNP and our protein antigen ODx3 and test its immunogenicity in both mice and 
rabbits. 
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3.3 Results 
3.3.1 Loading Antigen on GNPs  
The protein antigen ODx3 can be easily attached to the GNP through the 
SH-NTA linker (Figure 3.2, A). The binding capacity was measured by loading 
different amounts of antigen on the GNPs, and then measuring the unbound 
protein remaining in the supernatant after spinning down the particles. We found 
that 1ml of GNPs (4.5x1010 particles) can bind up to 20µg of ODx3. The 
conjugation of ODx3 to GNPs was analyzed by 1% agarose gel electrophoresis 
(Figure 3.2, B). GNPs alone cannot move on the gel, but after coupled to SH-
NTA, the particles become negatively charged and are able to migrate. When 
ODx3 is loaded on the particles, the pKa of ODx3 (9.6) is higher than the pH of 
the TAE (pH 8.0), they will be retained more than the SH-NTA particles alone 
because of the added molecules and the positive charge of the protein in the 
running buffer.   
 
Figure 3.2: Gold binding diagram and agarose gel analysis 
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(A) Schematic diagram showing how ODx3 is linked on GNPs. (B) GNPs and antigen running on 
1% agarose gel under 80V for 1 hr. Lane 1: GNPs only; Lane 2: GNPs coated with the SH-NTA 
linker; Lane 3: ODx3 loaded GNP-NTA particles. 
 
3.3.2 Antigenicity Test 
To test whether the epitopes of common gp120 neutralizing antibodies are 
still exposed after ODx3 was loaded on the GNPs, we used both the enzyme-
linked immunosorbent assay (ELISA) (Figure 3.3, A) and Immunoprecipitation 
(IP) (Figure 3.3, B). For the ELISA, we coated a 96-well plate with the protein-
linked particles and tested the binding with the antibodies. For IP, different 
antibodies were used to test whether they could pull down the antigen-coated 
particles. 10A3 is one monoclonal antibody we isolated from a gp120-immunized 
rabbit that targets the gp120 V3 loop (unpublished data). 257-D IV [53,226] and 
447-52D [227,228] are also V3 loop targeting antibodies. PGT 121 [229,230] 
binds to the N332 glycan-V3 loop. The epitope of 2G12 [54,177,231-233] is 
glycan dependent. 2C2 was used as a negative control, a non-neutralizing 
monoclonal antibody we isolated from a gp41-based antigen immunized rabbit 
that targets the heptad repeat 2 (HR2) and membrane proximal external region 
(MPER) (unpublished data). Thus, as we can see from Figure 3.3, even after 
attachment to the GNPs, ODx3 can still display the epitopes of the neutralizing 
antibodies well, especially for the V3 loop and the glycan epitopes. There is also 
a small amount of signal for VRC01 [234], even though its epitope is the CD4 
binding site.  
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Figure 3.3: Antibodies detection of ODx3 conjugated to GNP-NTA 
(A) Plate coated with ODx3 loaded GNPs tested with different antibodies using ELISA. (B) Gel 
shows western blot result of IP assay using ODx3 on GNPs to pull out different antibodies.  
 
3.3.3 Immunogenicity Responses in Mice 
We initially tested the immunogenicity of the GNP-linked antigen in mice. 
The mice immunization was conducted first by comparing the ODx3 loaded on 
GNP group, the ODx3-only immunization group, and the GNPs-only 
immunization group. The GNPs-only immunization group did not show any 
immune response (data not shown). For the other two groups, we collected the 
serum samples two weeks after the second and third immunization, and then 
tested the antibody titer using ELISA. From the ELISA data we can see a major 
difference in the titer between the two groups after both the 2nd and 3rd 
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immunizations (Figure 3.4). Following the second immunization, there is a five-
fold increase between ODx3-GNP and ODx3 alone, and an even larger increase 
of close to ten-fold after the 3rd immunization. The fact that the antibody titer of 
ODx3 on GNP can reach 107 after only three immunizations is quite significant, 
especially since no adjuvant was used. This shows that the GNP-NTA delivery 
platform was a great benefit to the immune system.  
 
 
Figure 3.4: Serum immunogenicity in mice 
Antibody responses elicited in mice using only ODx3 protein and ODx3 loaded GNPs. Pre is a 
negative control that means before immunization; 2nd and 3rd indicate the sera withdraw from 
after 2nd and 3rd immunizations. 
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3.3.4 Immunogenicity Responses in Rabbits 
The rabbit serum samples were also collected two weeks after each 
immunization. Figure 3.5 shows how the titer gradually increases after each 
immunization; after the third immunization, the titer also reached to 107. 
Therefore, the GNP-NTA platform successfully enhanced the immune response 
in both mice and rabbits. We also looked into the specific binding pattern of the 
immune response using linear epitope mapping. This showed us where the 
immune response was focused in the rabbit serum. In Figure 3.6, we can see 
that the strongest signal is in the V3 and C4 regions. This result is consistent with 
our previous study using zinc chitosan (ZNC) to deliver ODx3 in rabbits [80]. The 
V3 loop is known to play a key role in HIV entry by binding to the co-receptor 
CXCR4 and CCR5 [235]. We can see in all the rabbits immunized, the serum 
antibodies from all the rabbits immunized showed an affinity for the linear 
epitopes in the V3 region (Figure 3.7). As mentioned earlier, even after loading 
ODx3 on the GNP, the epitopes are still preserved and accessible for neutralizing 
antibodies, exhibiting strong affinity to antibodies targeting the V3 loop (Figure 
3.3). Therefore, this GNP-NTA platform will preserve the epitopes of the antigen 
we loaded. Peptide ELISA was also performed using the MCON6 variable region 
peptides, because the ODx3 was originally generated based on MCON6 
sequence [80]. We can also see strong binding in V3 and C4 region. 
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Figure 3.5: Serum immunogenicity in rabbits 
Antibody responses elicited in rabbits using ODx3 loaded GNPs. Pre means before immunization; 
2nd and 3rd indicate the sera withdraw from after 2nd and 3rd immunizations 
 
 Figure 3.6: Linear epitopes identification 
15-mer overlapping peptides covering the whole gp120 outer domain region was used. (A) Linear epitope of different rabbit serum sample. R1, 
R2, R3 are rabbit numbers. The serum is from the ODx3 loaded on GNP-NTA post-third immunization. (B) List of immunogenic epitopes in V3 and 
C4 region. 
6
2 
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3.3.5 Neutralizing Activity 
Pseudovirus neutralization assay was performed to test the anti-HIV-1 
activity of the immunized rabbit sera from all groups in TZM-bl cells. Several 
viruses from Clade B and C were tested. We did not detect any neutralizing 
activity in mouse sera; however, the rabbit sera (Table 3.1, A), had potent 
neutralizing activity against tier 1A viruses. For the tier 1B viruses BaL.26, 
SS1196.1 and 6535.3, there was little or no neutralizing activity within the sera. 
To eliminate other factors in the serum as the cause of the neutralization, we 
purified the serum IgG and repeated the assay. With the purified IgG, these tier 
1B viruses can now be neutralized (Table 3.1, B).  
 
Table 3.1: TZM-bl assay tested using HIV-1 pseudo-viruses with serum (A) and purified IgG 
(B) from after third immunization.   
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3.3.6 Inhibition Assay 
We further conducted a neutralization inhibition assay using the MCON6 
V3 loop peptide (TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH) to assess if the 
V3 loop is crucial for neutralization activity or not. For this analysis, we used the 
purified IgG (100 mg/ml) from rabbits in the presence of various concentrations of 
the peptide. VRC01 (10 mg/ml) was used as a negative control. As shown in 
Figure 3.7, neutralization of both MN.3 and MW965.26 viruses by ODx3 induced 
nAbs was efficiently inhibited by the peptide. As expected, the neutralizing 
activity of VRC01 was not affected. The peptide affected the neutralizing activity 
of MN.3 more than it did MW965.26. This could be that the IC50 of the purified 
IgG against MN.3 is higher than it is against of MW965.26. Especially for the IgG 
from R3, the IC50 is 56.95 µg/ml against MN.3, which may explain why the 
peptide can inhibit neutralizing activity even at low concentrations.  
 
 
Figure 3.7: Inhibition of neutralizing activity by V3 loop peptide  
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Neutralizing activity of purified IgG (100 µg/ml) from rabbits immunized with ODx3 on GNPs in the 
presence of various concentrations of MCON6 V3 peptide 
(TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH). VRC01 bnAb (10 mg/ml) that targets the 
CD4bs was used as a negative control. 
 
3.4 Discussion 
A good delivery platform is crucial for enhancing the effectiveness of a 
vaccine candidate. GNPs have many advantages when used as a delivery 
platform for vaccines. They are stable [236], biocompatible [147], and have a 
variety of sizes and shapes [131,237]. Additionally, the natural bond between 
gold and the thiol group is quite stable and this reaction does not alter the 
epitope structure [238,239]. This makes it easy to attach any compound to the 
GNPs using the thiol group. We introduced a linker called SH-NTA. This linker 
has a thiol group at one end to attach to the GNPs, and on the other end, the 
NTA portion has a very strong affinity to the imidazole ring of histidine that can be 
used to attach the protein antigen. The bond between NTA and histidine is not 
stable in a low pH environment, which means that after the protein-loaded GNPs 
are taken up by APCs, the antigen or other activating factor (described in 
Chapter 4) can be released for further processing because of the acidification 
inside the endosomes (Figure 3.1).  Additionally, a high density of antigens can 
be loaded onto a single GNP. From our binding test, 1 ml of GNPs (4.5x1010 
particles) can bind with 20µg of ODx3 without showing aggregation. This means 
that around 1500 molecules of ODx3 could be loaded onto a single 50nm GNP.  
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The results from the ELISA and IP assay demonstrated that even after 
binding to GNPs, the antigen ODx3 still preserved the epitope of commonly used 
bnAbs. Those epitopes are mostly in the V3 loops, as confirmed later by the 
epitope mapping and inhibition assay. However, our previous study showed that 
ODx3 could also bind with VRC01 in the IP assay although the signal is weaker 
than the V3-loop targeting antibody 447-52D [80]. The weaker binding of VRC01 
compared to 447-52D was also observed in this study. But binding of VRC01 is 
very weak, that we can barely see the signal. This is most likely because 
compared to normal IP assay, our newly developed IP assay specifically for 
antigens already loaded on GNPs is more complicated and requires more steps. 
Therefore, the loss of some of the antibodies or proteins during the washing is a 
possible contributing factor to the loss of the final signal. It is also possible that 
after loading on GNPs, CD4bs could be less accessible compared to the V3 loop 
on ODx3 to the bnAbs. Additionally, the strong binding results of ODx3 with these 
V3 loop targeted bnAbs from our IP assay are also consistent with those from the 
ELISA technique designed for antigens loaded on GNPs used previously by 
other study [138].  
We hypothesized that a multivalent antigen would be better at stimulating 
the immune system to induce high immune responses. We achieved much 
higher antibody titers from the ODx3 on GNPs than the ODx3 only group in mice. 
Consistently, there was also a very high immune response from rabbits, with the 
antibody titer reaching 107 (Figure 3.5). The high titer elicited in both mice and 
rabbits is quite significant. Researchers have been using adjuvants to boost the 
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immune responses from mice and rabbit for HIV envelope antigens to reach a 
titer of around 105 to 106 [240-242]. In our previous study with ODx3, we also 
observed a titer of 107 using zinc-chitosan as an adjuvant with 200 µg of ODx3 
[80]. Therefore, the GNPs helped us obtain the same high titer as we obtained 
from using a potent adjuvant with only half doses, which makes this platform 
effective in boosting the immune response in two different animal models.  
Unfortunately, we did not see neutralizing activity from the mice sera. One 
possible reason is that mice do not make antibodies with long HCDR3s [243], 
while most HIV bnAbs have long HCDR3 [244,245]. Therefore, mice may not be 
a suitable animal model for eliciting HIV nAbs. Law et al. [183] also did not obtain 
nAbs response from the mice they immunized with HIV envelope based antigen. 
However, they were able to observe neutralizing activity from the rabbits with the 
same antigen. Besides, for our study, there were not enough mice sera left for 
IgG purification or epitope mapping. Therefore, we continued our study further in 
rabbits, since more blood samples can be collected for further experiments and 
they possess long HCDR3s [246]. As expected, neutralizing activity was detected 
from the rabbit serum against several tier 1A viruses (Table 3.1, A). Purified IgG 
also demonstrated neutralizing activity against several viruses from clade B and 
clade C. Since the purified IgG is still polyclonal, we suspect that the actual 
neutralizing antibodies in the serum could probably neutralize these viruses at a 
much lower concentration.  
This study demonstrated that our platform could significantly elevate the 
immune responses of the loaded antigen in two different animal models. 
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Although no nAbs were elicited against tier 2 viruses, we can always use this 
platform to carry other protein antigens that have better antigenicity and 
immunogenicity to elicit nAbs against tier 2 viruses and further amplify their 
immune responses. This delivery platform can be applied to any protein-based 
therapeutic molecules beyond the HIV vaccine development field as described in 
this study. 
In sum, we were able to induce a strong immune response in both mice 
and rabbits due to the presentation and multivalent coating of epitopes in this 
novel GNP delivery platform. This platform has great potential for future protein-
based biomolecule delivery. 
 
3.5 Materials and Methods 
3.5.1 Loading ODx3 onto 50 nm GNPs 
1ml of 50nm GNPs were incubated and mixed with 2.5 μl of SH-NTA 
(1mg/ml freshly prepared in DMSO before use) for 1 hr at room temperature 
(RT). Then, 67µl of 0.3M Copper (II) sulfate pentahydrate was added to the 
solution to make the final concentration 20mM. After another 1 hr incubation, 8 
μg of ODx3 (diluted in 160µl of PBS, pH 8.0) was added and allowed to mixed for 
1 hr at RT. The whole mixture was pelleted by centrifugation at 6000g for 1 hr at 
4°C. The pellet was washed 1x with PBS (pH 8.0) before immunization study. 
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3.5.2 Gel Electrophoresis 
Agarose gel analysis method was modified from Chen et al. [138]. The 
ODx3-GNP pellet was re-suspended in 20 µl of 1% tris-buffered saline (TBS) and 
loaded onto a 1% agarose gel. Gel separation was performed at 80V for 1 hr at 
RT. 
 
3.5.3 Immunoprecipitation Assay (IP) 
 The ODx3 loaded GNP was added to 1mL Odyssey Blocking Buffer (LI-
COR) and rocked for 1hr at RT. Antibody (1 µg) was mixed with 60µL Protein A 
beads in 1mL IP buffer (10mM Tris pH 7.5, 200mM NaCl, 1mM EDTA, 0.5% 
Triton X-100, filter sterilized) for 2hrs at RT. The GNP/NTA/CuSO4.5H2O/ODx3 
mixture was centrifuged (6000g, 1hr, 4°C) to remove the blocking supernatant. 
The Antibody/Protein A mixture was centrifuged at 200g for 5min and the 
supernatant was removed. The pellet was re-suspended in 1ml IP buffer. The 
mixture was then added to the GNP/NTA/ CuSO4.5H2O /ODx3 pellet and rocked 
overnight at 4°C. The mixture was centrifuged at 200g for 3min. The supernatant 
was removed and pellet washed 2x with 1mL IP buffer. After the supernatant was 
removed, a SDS sample buffer was added to all samples and boiled for 10 min. 
Sample (20 µl) was loaded on a 4-20% Tris-glycine gel, and ran at 120V for 2 
hrs. The gel was then transferred to a nitrocellulose membrane at 250 Amps for 
70 min. Western was performed according to Odyssey protocol. Briefly, the 
membrane was blocked at 4°C overnight. The primary antibody was a 
monoclonal mouse antibody specific for ODx3 (S7.5.14) at a 1:2500 dilution, 
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rocked for 1 hr at RT. The secondary antibody, anti-mouse (OD680) from 
Odyssey, was utilized in a dilution of 1:10,000 and incubated for 1 hr at RT. The 
membrane was read using an imaging machine (ODYSSEY CLx, LI-COR). 
 
3.5.4 Mice and Rabbit Immunization  
Female BALB/CJ mice (Jackson Lab) were immunized intraperitoneally 
with 10 µg of protein, either alone or loaded on the GNPs, at weeks 0, 3, and 7. 
Blood was collected at weeks 5 and 9 through the lateral tail vein. 
Female New Zealand white rabbits (Charles River) were immunized 
subcutaneously with 100 µg of protein loading on GNPs at weeks 0, 4, and 9.  
Blood was collected from the central ear artery two weeks after each 
immunization. All animal studies were conducted with the approval of IACUC.  
 
3.5.5 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA was used to monitor the immune responses of the antigen. Antigen 
(30 ng) was coated onto 96-well Nunc-Immuno plates overnight at 4 °C (coating 
buffer: 15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6).  The following 
morning, 200 µl of blocking buffer (1xPBS, pH 7.4, with 2.5% skim milk and 5% 
Calf Serum) was added to each well to block the uncoated surface and incubate 
at 37 °C for 1 hr. After discarding the coating buffer, wells were then washed 10x 
using washing buffer (PBS containing 0.1% Tween 20). Animal sera samples 
were diluted in blocking buffer, and 100 µl of 3-fold serial dilutions was added to 
each well and incubated for 2 hrs at 37 °C. The wells were washed 10x, and 
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horseradish peroxidase (HRP)-linked secondary antibody (goat anti-rabbit, 
1:3000 dilution) was added to each well and incubated for 1 hr at 37 °C. Wells 
were washed 10x and developed by adding 100 µl TMB HRP-substrate (Bio-
Rad) for 10 min. Reactions were stopped with 50 µl of 2 N H2SO4. Plates were 
read on a micro-plate reader (Versamax by Molecular Devices) at 450 nm. 
Experiments were performed in duplicate. 
 
3.5.6 GNP ELISA 
GNP ELISA was done according to the methods from Chen et al [138]. 
Briefly, to coat plates with protein loaded GNPs, 200 μl of 1 mM 3-aminopropyl-
triethoxysilane (APTES) in ethanol was added to each well and incubating 40 min 
at room temperature.  According to the authors, APTES facilitate the crosslinking 
of GNPs to plastic wells. The pretreated wells were washed with ethanol twice, 
and then distilled water twice. Antigen loaded GNP were coated at 30 ng/well 
onto 96-well Nunc-Immuno Plates using coating buffer (150mM Na2CO3, 350mM 
NaHCO3, 30 mM NaN3, pH9.6), and they were incubated at room temperature for 
2 hrs. Then, the wells will be wash with distilled water three times and 0.5% 
Triton X-100 in PBS three times. The assay proceeded with the conventional 
ELISA steps as stated above.  
 
3.5.7 Peptide ELISA 
Peptide ELISA with overlapping peptides (15-mer) was also performed. 
15-mer peptides (100 ng/well) covering the entire length of the OD region of 
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gp120 were coated onto a streptavidin-coated plate instead of the whole 
antigens. The rest was the conventional ELISA steps as stated above. 
 
3.5.8 Neutralization Assays 
HIV-1 pseudovirus infection assays in TZM-bl cells were carried out as 
previously described [196]. Briefly, heat inactivated (56°C for 1 hr) rabbit sera or 
purified IgG were diluted in Dulbecco’s modified Eagle’s medium (DMEM) with 
10% heat inactivated FBS and incubated for 1 hr in the presence of viruses at 
37°C.  TZM-bl cells (1x104) were then added to the mixtures in medium 
containing DEAE-dextran (Sigma) at a final concentration of 10 µg/ml.  Plates 
were incubated at 37°C for 48 hrs, developed with Bright-Glo Luciferase Assay 
kit (Promega, Madison, WI) and immediately analyzed for luciferase activity with 
an illuminometer (Synergy 2, BioTek). The 50% inhibitory dose (ID50) or 
concentration (IC50) were defined as the sera dilution or purified IgG 
concentration at which relative luminescence units (RLU) were reduced 50% 
compared to virus control wells after subtraction of background RLU in cell 
control wells. For the peptide inhibition neutralizing assays, the same procedure 
was followed except that antibodies were pre-incubated with V3 peptide (in 
varying concentrations) for 1 hr at 37°C.  
Viruses tested were SF162.LS (tier 1A, Clade B), MW965.26 (tier 1A, 
Clade C), MN.3  (tier 1A, Clade B), BaL.26 (tier 1B, Clade B), SS1196.1 (tier 1B, 
Clade B), and 6535.3 (tier 1B, Clade B). Also murine leukemia virus Env-
pseudotyped virus (MuLv) was used as a negative control.  
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CHAPTER 4 GENERAL CONCLUSIONS 
 
GNPs as a promising delivery platform have already been used for human 
clinical trials in cancer research [247,248]. There is also an explosion of 
applications of GNPs in drug and vaccine delivery recently as described in 
Chapter 1. However, we are not aware of any studies using GNPs to deliver 
protein-based HIV antigens. Since HIV vaccine development is still moving 
slowly, with limited success during the past 30 years, we decided to include 
GNPs in our research to explore their potential to accelerate HIV vaccine 
research.  
 
4.1 Conclusions 
4.1.1 Linking HIV-1 Envelope Antigens Directly on GNPs 
As we know from Chapter 1, thiol can form a strong bond with GNP. The 
only amino acid that has thiol group is cysteine; therefore, we introduced cysteine 
mutations into the original gp41-54Q antigen to make several cysteine variants 
by site-directed mutagenesis. All these cysteine variants can successfully bind to 
GNPs and expose the epitope to several common bnAbs after binding to the 
GNPs. However, while the two terminal variants (54QC and C54Q) can elicit 
strong immune responses with the antibody titer reaching 106, we did not detect 
any neutralizing antibody elicited in the immunized rabbits. Epitope mapping 
further demonstrated that most antibody responses target the middle of the 
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antigens, where many non-neutralizing epitopes located. Therefore, we further 
introduced three other cysteine mutations to make 12C, 19C and 26C, to 
investigate whether attaching the antigens to GNPs through the middle cysteine 
could help to block those non-neutralizing epitopes. Unfortunately, we found 
almost no immune response after the second immunization, and the after third 
immunization, antibody tiers were around 103, which were significantly lower than 
results from the other two terminal cysteine variants. We supposed that it might 
because those internal variants cannot be well processed in vivo by binding in 
their middle sections on GNPs. To make sure those antigens are still 
immunogenic, we further immunized them using ZNC which bind the c-terminal 
of the antigens through his-tag. This time, we got higher antibody responses; 
most titers were above 105 after the third immunization. This is the first study that 
reported the eligibility of loading protein antigens from HIV-1 on GNPs to induce 
antibody responses from rabbits. The results of internal variants suggested that 
the linking site of antigen to GNPs is crucial and can influence immune 
responses. A space linker between the antigen and GNPs may be necessary to 
improve immune responses, this possibility was explored in Chapter 3.  
 
4.1.2 Linking Antigen to GNPs Using The SH-NTA Linker 
Linking HIV-1 antigens directly to GNPs may result in inducing low 
antibody responses as described in Chapter 2. Therefore, we designed two 
linkers to attach our antigens to GNPs (4-ATP and SH-NTA). The 
immunogenicity result by using the 4ATP linker is described in the Appendix. We 
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found that the SH-NTA is potentially better than the 4-ATP linker, so we 
continued our studies using the SH-NTA linker. The antigen we used for this 
study is ODx3, a promising protein antigen that consists of three tandem repeats 
of HIV-1 gp120 outer domain gp120 [80]. Again, the in vitro tests demonstrated 
that ODx3 could be successfully loaded on GNPs through the linker and its 
epitopes for the V3 targeted bnAbs were still properly exposed after loaded. We 
compared immune responses of the protein-on-GNP and the protein-only group 
in mice. From Chapter 3, we can see the protein-on-GNP group clearly gave us 
stronger titer than the protein-only group. Unfortunately, we did not detect any 
neutralizing activity in the mice sera. Given the limited mice sera are not enough 
for detailed epitope mapping and purification of the serum IgG, we continued our 
study in rabbits. Again, we obtained antibody tier up to 107, which was similar to 
that observed in mice. Those antibody responses were mostly towards the V3 
and C4 region in the outer domain, which was also consistent with our published 
data of ODx3 [80]. Furthermore, nAbs were also elicited against several tier 1 
HIV-1 isolates. This platform has demonstrated its capability to delivery HIV Env 
based antigens with their antigenic properties preserved and immunogenicity 
enhanced. The results from Chapters 2 and 3 together demonstrate our GNP-
based antigen delivery platform has great potential for further development.  
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4.2 Future directions 
4.2.1 Co-stimulatory Molecules 
Besides the immunized antigen, there are many other effectors that could 
contribute to polyclonal B cell activation [249]. One famous stimulator, BlyS (B 
Lymphocyte Stimulator [250]; also known as BAFF, B-cell activating factor [251]; 
THANK, TNF Homologue That Activates Apoptosis, Nuclear Factor-κB, and c-
Jun NH2-Terminal Kinase [252]; TALL-1, TNF- and ApoL-related leukocyte-
expressed ligand 1 [253]; and zTNF4 [254]), a member of the tumor necrosis 
factor (TNF) family that stimulates B cell growth and immunoglobulin secretion. 
As a costimulator of B cell proliferation and function, BlyS has been widely used 
as an adjuvant in vaccine research. Gor et al. [255] fused the human BLyS with 
Pneumococcal Surface Adhesin A (PsaA), and found that the fusion protein 
elicited significantly higher serum antibody responses as well as cell-mediated 
immune responses compared to the Psa A alone in mice. Dosenovic et al. [256] 
injected BLyS into mice before they immunized their gp140 antigen. Their results 
also indicated that the pre-injection of BLyS led to a great improvement of the 
neutralizing antibody responses induced by the antigen against HIV-1. Another 
commonly used co-stimulator is the CD40 ligand (CD40L, or CD154) [257,258]. 
CD40L on a T cell surface is known to bind the CD40 molecule on a B cell and 
cooperates with BLyS in B cell activation [259]. This co-stimulator has also been 
applied as an adjuvant in vaccine research against viruses including HIV-1 
[260,261]. Melchers et al. [262] fused APRIL (A Proliferation–Inducing Ligand, 
shared two receptors with BLyS [263]), BLyS, and CD40L with gp140 protein and 
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reported improvement of the induction of humoral immunity against HIV-1 from 
all the three fusion antigens. Since all these co-stimulatory molecules are 
proteins, therefore, by introducing his-tag, we can link them together with our 
antigens on the GNP surface through the SH-NTA linker to facilitate eliciting 
stronger immune responses. 
 
4.2.2 Gold Nano-cages 
Apart from antigens present solely on the surface of GNPs, we can also 
load antigens inside GNPs by using gold nano-cages (GNCs). The principle of 
making GNCs is based on galvanic replacement reaction. The driving force of 
this reaction is the electrical potential difference between two different metals; 
one acts as anode and the other as cathode. The high potential cathode metallic 
ions are reduced into metal and accumulate on the anode, while the anode metal 
dissolves into the electrolyte. To make GNCs, we need sliver nano-cubes, which 
can be easily synthesized by reducing silver nitrate with ethylene glycol in the 
presence of poly (vinyl pyrrolidone) (PVP) as the capping reagent [264]. Silver 
serves as the anode, since Ag (Ag+/Ag, 0.8V) can be oxidized by HAuCl4 (AuCl4-
/Au, 0.99V). 
3Ag(s) + AuCl4-(aq)  Au(s) + 3Ag+(aq) + 4Cl-(aq) 
From the formula, we know that one gold atom can replace three silver 
atoms; therefore, empty spaces continue to grow inside the cube while the 
reaction continues, and when all the silver atoms are replaced by gold, GNCs are 
formed (Figure 4.1).  
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Figure 4.1: Making GNCs through galvanic replacement reaction 
(A) Initiation at a spot with high surface energy; (B) Partially hollow nanostructure; (C) 
Nano-boxes with Au/Ag alloy homogeneous wall; (D) Dealloying and morphological 
reconstruction; (E) Continuation of dealloying, formation of pores; (F) Gold nano-cage (G) 
Scanning electron microscopy (SEM) image for the gold nano-cages. Adapted from [265]. 
 
To further control the cage wall thickness and nano-cage porosity, we can 
use Fe(NO3)3. 
Ag(s) + Fe(NO3)3  AgNO3(aq) + Fe(NO3)2(aq) 
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This process is called wet chemical etching [266]. Depending on the 
amount of etchant used, we can control our gold nano-cage with different size of 
surface pores and internal spaces. 
A GNC surface can be used to coat biological molecules for delivery 
purpose. Chen et al. [267] found that GNC could deliver antibodies on the 
surface to target cancer cells, and the efficiency for delivery was similar to 
commercial GNPs (same size spheres). For our vaccine delivery, we can link 
protein antigens like ODx3 to the surface of GNCs to stimulate the B-cell immune 
response as we did in Chapter 3.  
The inside space of GNCs can also be used for delivery and controlled 
release of the contained molecules. Yavuz et al. [268] coated a GNC with 
polymers based on poly (N-isopropylacrylamide) (pNIPAAm) and its derivatives. 
This kind of polymer can change conformation and uncover the pores on the 
GNC surface to allow the release of the inside drugs in response to heat. A laser 
beam can be used to generate heat when its wavelength matches the absorption 
peak of the GNC through photothermal effect [269]. For our study, the surfaced 
coated antigens could block the release of the inside antigens. However, when 
the whole antigen-loaded GNC is engulfed by APCs in the endosomes, the 
reduction of pH will lead to the release of the surface antigens (see mechanism 
in Chapter 3), thus, the inside antigen can be released gradually afterwards.  
Since the antigen inside the GNC cannot directly contact BCRs to elicit 
humoral responses, we will select antigens that specifically stimulate the other 
arm of the immune response, the cell-mediated immunity [270]. In HIV vaccine 
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research, Gag protein as an essential part of the virus [271] is well known to elicit 
T cells responses, which correlated with delayed progression [272]. Kiepiela et 
al. [273] found that from 160 dominant CD8 T-cell responses, only Gag-specific 
responses were associated with lowering viremia. The CD8 cells from those high 
Gag responders demonstrated a more significant suppression of the virus 
replication in vitro as well than did low Gag responders [274]. The enhanced CD8 
T cell activity from these studies highlighted the usage of the Gag protein or its 
components as vaccine candidates. The T cell epitopes on Gag has already 
been identified [275], with one study reporting that patients whose immune 
responses targeted the conserved HIV-Gag-epitopes had significantly lower viral 
load compared to those targeting variable epitopes [276]. For our study, the 
conserved T cell epitope of Gag protein will be selected to load inside the GNCs 
to eliciting cell-mediated immunity. 
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APPENDIX  IMMUNIZATION STUDY USING GNR-4ATP 
PLATFORM   
 
In this study, we investigated the immunogenicity of ODx3 loaded on 
GNR-4ATP delivery platform. Dr. Chenxu Yu’s lab in Iowa State University 
developed the GNR-4ATP platform and has been using it to load antibodies for 
bacteria detection[141,142]. With the help from his lab, we decided to test their 
platform together with our GNP-NTA platform for HIV-1 vaccine delivery 
research. The producing process of GNRs and the conjunction with protein 
through the linker 4-ATP on GNRs was elaborated in Chapter 1 (section 1.3.2.2 
and 1.3.2.3), and the immunogenicity data of ODx3 loaded on GNP-NTA platform 
was described in Chapter 3.  
ODx3 was intraperitoneally administrated to BALB/c mice at a dose of 
10µg per mice either alone or conjugated with GNR-4ATP. The mice were 
immunized three times at weeks 0, 3, and 7. The presence of anti-ODx3 
antibodies was assessed in the sera collected two weeks after the second and 
third immunizations (Figure Appendix 1). In the GNR-4ATP group, an increased 
trend of the antibody titer was observed from the second to third administrations, 
which suggested that the retaining effect of the antigen in the GNR cluster nano-
carriers was relatively high due to the strong and stable covalent bonding 
between ODx3 and diazonium moiety in 4-ATP. Especially for one mouse, the 
serum titer can reach up to 106 after the third boost. However, comparing with the 
protein-only group, we did not see stronger antibody response brought by this 
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GNR-4ATP delivery platform. In contrast, the GNP-NTA complex showed much 
better antibody responses (Chapter 3, Figure 3.4) compared with the results we 
got from this study. Thus, the results indicated that this GNR-4ATP platform 
might not be suitable for stimulating strong immune response of the loaded 
antigen. Therefore, we continued our study using the GNP-NTA platform as 
described in Chapter 3.  
 
 
Figure Appendix: Antibody titers of the ODx3 only group and the GNR-4ATP group 
(A, C) Sera antibody titer of mice immunized with ODx3 only and delivered on GNR-
4ATP after 2nd immunization. (B, D) Same analysis for mice sera after 3rd immunization. Pre is the 
pre-immunization serum; Mice serum numbers are indicated by M1, M2, M3, M4, and M5. 
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